Posted inBiotechnology
Posted inBiotechnology
Gilead turns down chance to build on Assembly’s phase 1-stage HBV antiviral
Gilead Sciences has handed back a next-gen hepatitis B (HBV) antiviral to Assembly Biosciences, while the two companies continue to…




















